Rosiglitazone, a Ligand to PPAR, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation

Figure 8

Effect of rosiglitazone (RGZ) on PPARγ activity (a) and PPARγ expression of sham or aortic coarctated (AoCo) rats treated with vehicle (V), rosiglitazone (5mg/kg, RGZ), or RGZ + bisphenol A diglycidyl ether (120 mg/kg, RGZ+BADGE). PPARγ activity was evaluated using a transcription factor assay kit (Cayman Chemicals, Ann Arbor, MI, USA). Western blot image is representative of 6 different experiments. Bars represent the mean ± SEM (n=6 animals of group). One-way analysis of variance (ANOVA) post Tukey. ⁺P < 0.05 Sham-V vs. Sham-RGZ, ^#P < 0.05 AoCo-V vs. AoCo-RGZ, and ^&P < 0.05 AoCo-RGZ vs. AoCo-RGZ+BADGE.

(a)

(b)